ALTEOGEN Inc (196170) - Net Assets

Latest as of September 2025: ₩377.92 Billion KRW ≈ $256.11 Million USD

Based on the latest financial reports, ALTEOGEN Inc (196170) has net assets worth ₩377.92 Billion KRW (≈ $256.11 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩639.48 Billion ≈ $433.36 Million USD) and total liabilities (₩261.55 Billion ≈ $177.25 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 196170 asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric Value
Current Net Assets ₩377.92 Billion
% of Total Assets 59.1%
Annual Growth Rate 22.56%
5-Year Change 108.97%
10-Year Change 610.99%
Growth Volatility 35.71

ALTEOGEN Inc - Net Assets Trend (2014–2024)

This chart illustrates how ALTEOGEN Inc's net assets have evolved over time, based on quarterly financial data. Also explore balance sheet size of ALTEOGEN Inc for the complete picture of this company's asset base.

Annual Net Assets for ALTEOGEN Inc (2014–2024)

The table below shows the annual net assets of ALTEOGEN Inc from 2014 to 2024. For live valuation and market cap data, see 196170 market cap.

Year Net Assets Change
2024-12-31 ₩274.09 Billion
≈ $185.75 Million		 +85.39%
2023-12-31 ₩147.84 Billion
≈ $100.19 Million		 -0.62%
2022-12-31 ₩148.76 Billion
≈ $100.81 Million		 +8.80%
2021-12-31 ₩136.73 Billion
≈ $92.66 Million		 +4.25%
2020-12-31 ₩131.16 Billion
≈ $88.89 Million		 +87.42%
2019-12-31 ₩69.98 Billion
≈ $47.43 Million		 +5.04%
2018-12-31 ₩66.63 Billion
≈ $45.15 Million		 +67.21%
2017-12-31 ₩39.85 Billion
≈ $27.00 Million		 -11.90%
2016-12-31 ₩45.23 Billion
≈ $30.65 Million		 +17.32%
2015-12-31 ₩38.55 Billion
≈ $26.13 Million		 +7.61%
2014-12-31 ₩35.82 Billion
≈ $24.28 Million		 --

Equity Component Analysis

This analysis shows how different components contribute to ALTEOGEN Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 5748.5% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings ₩76.87 Billion 28.10%
Common Stock ₩26.66 Billion 9.74%
Other Components ₩170.06 Billion 62.16%
Total Equity ₩273.59 Billion 100.00%

ALTEOGEN Inc Competitors by Market Cap

The table below lists competitors of ALTEOGEN Inc ranked by their market capitalization.

Company Market Cap
Juniper Networks Inc
NYSE:JNPR
 $13.36 Billion
mBank SA
WAR:MBK
 $13.36 Billion
Investment AB Latour (publ)
ST:LATO-B
 $13.36 Billion
Argen-X
LSE:0QW0
 $13.37 Billion
Shengyi Electronics Co. Ltd. A
SHG:688183
 $13.34 Billion
Ovintiv Inc
NYSE:OVV
 $13.30 Billion
Focus Media Information Technology Co Ltd
SHE:002027
 $13.29 Billion
Bharat Heavy Electricals Limited
NSE:BHEL
 $13.27 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in ALTEOGEN Inc's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 148,114,262,930 to 273,593,211,290, a change of 125,478,948,360 (84.7%).
  • Net income of 62,252,319,000 contributed positively to equity growth.
  • Share repurchases of 27,142,861,730 reduced equity.
  • New share issuances of 12,713,385,860 increased equity.
  • Other factors increased equity by 77,656,105,230.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income ₩62.25 Billion +22.75%
Share Repurchases ₩27.14 Billion -9.92%
Share Issuances ₩12.71 Billion +4.65%
Other Changes ₩77.66 Billion +28.38%
Total Change ₩- 84.72%

Book Value vs Market Value Analysis

This analysis compares ALTEOGEN Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 71.78x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has decreased from 304.19x to 71.78x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2016-12-31 ₩1211.42 ₩368500.00 x
2017-12-31 ₩1053.24 ₩368500.00 x
2018-12-31 ₩1756.56 ₩368500.00 x
2019-12-31 ₩1678.64 ₩368500.00 x
2020-12-31 ₩3113.74 ₩368500.00 x
2021-12-31 ₩3232.11 ₩368500.00 x
2022-12-31 ₩2888.81 ₩368500.00 x
2023-12-31 ₩2862.27 ₩368500.00 x
2024-12-31 ₩5133.55 ₩368500.00 x

Capital Efficiency Dashboard

This dashboard shows how efficiently ALTEOGEN Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 22.75%
  • The company demonstrates strong efficiency in generating profits from shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 60.52%
  • • Asset Turnover: 0.25x
  • • Equity Multiplier: 1.49x
  • Recent ROE (22.75%) is above the historical average (-1.23%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2014 2.60% 13.22% 0.19x 1.06x ₩-2.65 Billion
2015 3.13% 25.57% 0.12x 1.02x ₩-2.65 Billion
2016 -7.93% -52.42% 0.14x 1.06x ₩-8.11 Billion
2017 -18.69% -61.54% 0.28x 1.08x ₩-11.43 Billion
2018 -10.31% -50.15% 0.19x 1.07x ₩-13.53 Billion
2019 -1.01% -2.41% 0.34x 1.23x ₩-7.70 Billion
2020 -0.74% -2.29% 0.27x 1.21x ₩-14.09 Billion
2021 4.39% 14.59% 0.16x 1.90x ₩-7.67 Billion
2022 -5.48% -28.28% 0.12x 1.65x ₩-23.02 Billion
2023 -2.28% -3.49% 0.38x 1.73x ₩-18.18 Billion
2024 22.75% 60.52% 0.25x 1.49x ₩34.89 Billion

Industry Comparison

This section compares ALTEOGEN Inc's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $210,358,050,483
  • Average return on equity (ROE) among peers: 4.01%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
ALTEOGEN Inc (196170) ₩377.92 Billion 2.60% 0.69x $13.36 Billion
ORIENTBIO Inc. (002630) $85.10 Billion 15.13% 0.14x $43.15 Million
Green Cross (005250) $221.73 Billion 2.76% 8.07x $425.10 Million
Green Cross Holdings Preference Shares (005257) $1.44 Trillion 3.01% 0.78x $3.74 Million
Pharmicell (005690) $76.66 Billion 10.78% 0.43x $736.42 Million
GeneOne Life Science Inc (011000) $26.74 Billion 0.00% 0.49x $49.94 Million
HLB Co. Ltd (028300) $46.46 Billion 0.00% 0.75x $5.41 Billion
Daesung Microbiological Labs. Co. Ltd (036480) $30.30 Billion 5.14% 0.15x $19.29 Million
Seoulin Bioscience Co.Ltd (038070) $53.72 Billion 4.89% 0.32x $37.92 Million
Hyundai Bioscience Co. Ltd (048410) $58.24 Billion 3.27% 0.77x $872.13 Million
iNtRON Biotechnology Inc (048530) $64.96 Billion -4.91% 0.37x $77.34 Million

About ALTEOGEN Inc

KQ:196170 Korea Biotechnology
Market Cap
$13.36 Billion
₩19.71 Trillion KRW
Market Cap Rank
#1772 Global
#43 in Korea
Share Price
₩368500.00
Change (1 day)
-3.03%
52-Week Range
₩317500.00 - ₩559000.00
All Time High
₩559000.00
Categories
Companies in Korea Biotechnology
About

ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the d… Read more